Alnylam Pharmaceuticals Inc (ALNY)vsDyne Therapeutics Inc (DYN)
ALNY
Alnylam Pharmaceuticals Inc
$286.62
-0.62%
HEALTHCARE · Cap: $35.71B
DYN
Dyne Therapeutics Inc
$25.73
+2.51%
HEALTHCARE · Cap: $3.88B
Smart Verdict
WallStSmart Research — data-driven comparison
ALNY leads profitability with a 12.6% profit margin vs 0.0%. DYN appears more attractively valued with a PEG of 0.19. ALNY earns a higher WallStSmart Score of 65/100 (B-).
ALNY
Strong Buy65
out of 100
Grade: B-
DYN
Hold37
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+86.2%
Fair Value
$2337.47
Current Price
$286.62
$2050.85 discount
Intrinsic value data unavailable for DYN.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Every $100 of equity generates 54 in profit
Revenue surging 96.4% year-over-year
Strong operational efficiency at 23.0%
Growing faster than its price suggests
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Elevated debt levels
Premium valuation, high expectations priced in
Trading at 35.6x book value
0.0% revenue growth
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : ALNY
The strongest argument for ALNY centers on PEG Ratio, Return on Equity, Revenue Growth. Revenue growth of 96.4% demonstrates continued momentum. PEG of 0.49 suggests the stock is reasonably priced for its growth.
Bull Case : DYN
The strongest argument for DYN centers on PEG Ratio, Debt/Equity. PEG of 0.19 suggests the stock is reasonably priced for its growth.
Bear Case : ALNY
The primary concerns for ALNY are EPS Growth, Debt/Equity, P/E Ratio. A P/E of 67.0x leaves little room for execution misses.
Bear Case : DYN
The primary concerns for DYN are Revenue Growth, EPS Growth, Profit Margin.
Key Dynamics to Monitor
ALNY profiles as a growth stock while DYN is a value play — different risk/reward profiles.
DYN carries more volatility with a beta of 1.06 — expect wider price swings.
ALNY is growing revenue faster at 96.4% — sustainability is the question.
ALNY generates stronger free cash flow (49M), providing more financial flexibility.
Bottom Line
ALNY scores higher overall (65/100 vs 37/100) and 96.4% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alnylam Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
Dyne Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Dyne Therapeutics, Inc., a muscle disease company, is a biotechnology company focused on advancing therapeutics for genetically-derived muscle diseases in the United States. The company is headquartered in Waltham, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?